Skip to main content
. 2023 Jan 20;46(3):328–335. doi: 10.1002/clc.23966

Figure 2.

Figure 2

Changes in neutrophil‐to‐lymphocyte ratio values from Timepoint 1 (before doxorubicin therapy) to 2 (during doxorubicin therapy)